Skip to Content
Merck
  • APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin.

APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin.

Cell reports (2020-03-19)
Sophie Uzureau, Laurence Lecordier, Pierrick Uzureau, Dorle Hennig, Jonas H Graversen, Fabrice Homblé, Pepe Ekulu Mfutu, Fanny Oliveira Arcolino, Ana Raquel Ramos, Rita M La Rovere, Tomas Luyten, Marjorie Vermeersch, Patricia Tebabi, Marc Dieu, Bart Cuypers, Stijn Deborggraeve, Marion Rabant, Christophe Legendre, Søren K Moestrup, Elena Levtchenko, Geert Bultynck, Christophe Erneux, David Pérez-Morga, Etienne Pays
ABSTRACT

The C-terminal variants G1 and G2 of apolipoprotein L1 (APOL1) confer human resistance to the sleeping sickness parasite Trypanosoma rhodesiense, but they also increase the risk of kidney disease. APOL1 and APOL3 are death-promoting proteins that are partially associated with the endoplasmic reticulum and Golgi membranes. We report that in podocytes, either APOL1 C-terminal helix truncation (APOL1Δ) or APOL3 deletion (APOL3KO) induces similar actomyosin reorganization linked to the inhibition of phosphatidylinositol-4-phosphate [PI(4)P] synthesis by the Golgi PI(4)-kinase IIIB (PI4KB). Both APOL1 and APOL3 can form K+ channels, but only APOL3 exhibits Ca2+-dependent binding of high affinity to neuronal calcium sensor-1 (NCS-1), promoting NCS-1-PI4KB interaction and stimulating PI4KB activity. Alteration of the APOL1 C-terminal helix triggers APOL1 unfolding and increased binding to APOL3, affecting APOL3-NCS-1 interaction. Since the podocytes of G1 and G2 patients exhibit an APOL1Δ or APOL3KO-like phenotype, APOL1 C-terminal variants may induce kidney disease by preventing APOL3 from activating PI4KB, with consecutive actomyosin reorganization of podocytes.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nα-Tosyl-L-lysine chloromethyl ketone hydrochloride, ≥96% (TLC), powder
Millipore
ANTI-FLAG® M2 Affinity Gel, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Transferrin human, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Nile Red, for microscopy
Sigma-Aldrich
Anti-Tropomyosin Antibody, clone 15D12.2, clone 15D12.2, from mouse
Sigma-Aldrich
Anti-APOL1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
BRAND® 96-well microplate, U-bottom, round bottom, non-sterile
Sigma-Aldrich
CRISPR/Cas9 Products and Services, Design and order CRISPR gRNA, Cas9, screening libraries, controls and companion products. Formats include plant, lentivirus, IVT-RNA, plasmid, synthetic, and protein.
Sigma-Aldrich
MONOCLONAL ANTI-HIS TAG antibody produced in mouse, clone 6AT18, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Monoclonal ANTI-FLAG® M2 antibody produced in mouse, 1 mg/mL, clone M2, affinity isolated antibody, buffered aqueous solution (50% glycerol, 10 mM sodium phosphate, and 150 mM NaCl, pH 7.4)
Sigma-Aldrich
L-α-Phosphatidylethanolamine, dioleoyl, ≥99% (GC), ≥98% (TLC), lyophilized powder
Sigma-Aldrich
Anti-Rabbit IgG (whole molecule)−Gold antibody produced in goat, affinity isolated antibody, aqueous glycerol suspension, 5 nm (colloidal gold)
Millipore
Anti-V5 Agarose Affinity Gel antibody produced in mouse, purified immunoglobulin, clone V5-10
Sigma-Aldrich
Goat Anti-Mouse IgG Peroxidase Conjugate, lyophilized, Calbiochem®
Sigma-Aldrich
Monoclonal Anti-S Tag antibody produced in mouse, clone GT247, affinity isolated antibody